COMPOUND PROFILE / PEPTIDES & ANALOGUES
ARA-290 / Cibinetide.
Research draftCibinetide, also called ARA-290, is an erythropoietin-derived tissue-protective peptide.
Research evidence and COA results do not establish suitability for use. This is educational information, not a dosing guide or personal medical advice.
Targeted source and identity review, not a systematic review or complete regulatory audit.
Overview
Cibinetide, also called ARA-290, is an erythropoietin-derived tissue-protective peptide.
Mechanism
It was designed to engage repair-related receptor signalling without erythropoietin's red-cell-stimulating effect.
Human research
Randomised sarcoidosis-associated small-fibre neuropathy research examined nerve measures and symptoms; this does not establish broad nerve repair.
Preclinical & other research
Animal work investigated inflammatory injury and tissue protection.
Safety & unknowns
Limited trial size and disease specificity restrict conclusions about long-term safety and other uses.
Regulatory status
Investigational; no broad neuropathy approval is established by these studies.
Reported use & evidence
The supplied ARA-290 / Cibinetide profile and its cited sources are imported. Community experiences and laboratory evidence remain separate from these descriptions. Missing evidence is not a zero result.
Sources & references
Follow the cited records and registered research. Profiles remain research drafts.